Finding MYCure

Marie Eve Beaulieu; Laura Soucek

doi:10.1080/23723556.2019.1618178

Finding MYCure

Marie Eve Beaulieu, Laura Soucek

Departament de Bioquímica i de Biologia Molecular

Producció científica: Contribució a revista › Article › Recerca

8 Cites (Scopus)

Resum

© 2019, © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. Nevertheless, in our recent publication in Science Translational Medicine “Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy”, we demonstrate for the first time the feasibility of pharmacological MYC inhibition in vitro and in vivo using an Omomyc-based mini-protein.

Idioma original	Anglès
Número d’article	e1618178
Revista	Molecular and Cellular Oncology
Volum	6
Número	5
DOIs	https://doi.org/10.1080/23723556.2019.1618178
Estat de la publicació	Publicada - 1 de gen. 2019

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

ODG 3 – Bona salut i benestar

Accés al document

10.1080/23723556.2019.1618178

https://ddd.uab.cat/record/226620

Altres arxius i enllaços

Com citar-ho

@article{a347ca411ea9406b808a9e20c3162b21,

title = "Finding MYCure",

abstract = "{\textcopyright} 2019, {\textcopyright} 2019 The Author(s). Published with license by Taylor \& Francis Group, LLC. Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. Nevertheless, in our recent publication in Science Translational Medicine “Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy”, we demonstrate for the first time the feasibility of pharmacological MYC inhibition in vitro and in vivo using an Omomyc-based mini-protein.",

keywords = "MYC, NSCLC, OMOMYC, mini-protein, peptide therapeutic",

author = "Beaulieu, \{Marie Eve\} and Laura Soucek",

year = "2019",

month = jan,

day = "1",

doi = "10.1080/23723556.2019.1618178",

language = "English",

volume = "6",

journal = "Molecular and Cellular Oncology",

issn = "2372-3556",

publisher = "Taylor and Francis Ltd.",

number = "5",

}

TY - JOUR

T1 - Finding MYCure

AU - Beaulieu, Marie Eve

AU - Soucek, Laura

PY - 2019/1/1

Y1 - 2019/1/1

N2 - © 2019, © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. Nevertheless, in our recent publication in Science Translational Medicine “Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy”, we demonstrate for the first time the feasibility of pharmacological MYC inhibition in vitro and in vivo using an Omomyc-based mini-protein.

AB - © 2019, © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. Nevertheless, in our recent publication in Science Translational Medicine “Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy”, we demonstrate for the first time the feasibility of pharmacological MYC inhibition in vitro and in vivo using an Omomyc-based mini-protein.

KW - MYC

KW - NSCLC

KW - OMOMYC

KW - mini-protein

KW - peptide therapeutic

UR - http://www.mendeley.com/research/finding-mycure

UR - https://www.scopus.com/pages/publications/85068112352

U2 - 10.1080/23723556.2019.1618178

DO - 10.1080/23723556.2019.1618178

M3 - Article

C2 - 31528695

SN - 2372-3556

VL - 6

JO - Molecular and Cellular Oncology

JF - Molecular and Cellular Oncology

IS - 5

M1 - e1618178

ER -

Finding MYCure

Resum

SDG de les Nacions Unides

Accés al document

Altres arxius i enllaços

Fingerprint

Com citar-ho